Australia's Botanix jumps on starting trials to test canine eczema drug

Botanix Pharmaceuticals

29/09/2021 03:59

** Shares of pharma co  BOT.AX  rise as much as 5.97% to
A$0.071, set to snap a three-day losing streak
    ** Stock last up 5.2% at 0233 GMT, set for best day in more
than a week
    ** Co says proof of concept study testing its drug
candidate, BTX 1204A, in dogs with atopic dermatitis underway
following positive data from pilot study in Q2 2021  urn:newsml:reuters.com:*:nAZN01NRVY
    ** Plans to enroll 45 canines across three dermatology sites
in Australia and New Zealand in study
    ** Says that BTX 1204A has broad anti-inflammatory
properties and is beneficial for canine and human atopic
dermatitis, which are clinically similar
    ** Recruitment for BTX 1702 Phase-1b study in human patients
with moderate to severe papulopustular rosacea, another skin
condition, progressing to plan - BOT
    ** More than 330,000 shares change hands vs 30-day avg of
~900,000 shares - Refinitiv data
    ** Stock down 46% YTD, as of last close

 (Reporting by Jaskiran Singh in Bengaluru)
 ((jaskiran.singh@thomsonreuters.com))